Samsung Biologics (207940.KS) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $50.08B | Exchange | KSC |
| Sector | Healthcare | Industry | Biotechnology |
| Country | KR | CEO | John Chongbo Rim |
| IPO Date | 2016-11-11 | CAGR | 40.87% |
| Employees | 5,455 | Website | samsungbiologics.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.08% | Total Yield | 0.08% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $46.10B | P/E | 44.38 | Forward P/E | 30.94 | PEG | — |
| P/S | 28.71 | P/B | 16.49 | P/CF | 56.02 | P/FCF | 89.54 |
| Sales | $3.08B | Sales 1Y | -9.64% | Sales 3Y | 32.73% | Sales 5Y | 243.71% |
| EPS | $24.38 | EPS 1Y | 54.4% | EPS 3Y | 140.44% | EPS 5Y | 457.12% |
| Sales QoQ | 5.07% | EPS QoQ | -8.32% | Sales QoQ Avg | 64.94% | EPS QoQ Avg | 12.41% |
| Gross Margin | 39.66% | Operating Margin | 43.7% | Profit Margin | 43.64% | ROCE | 21.47% |
| ROA | 17% | ROE | 20% | Altman Z Score | 12.46 | Piotroski Score | 5 |
| Current Ratio | 1.7 | Quick Ratio | 0.86 | Cash Ratio | 0.19 | Op. CF Ratio | 0.28 |
| Debt/Equity | 0.15 | Debt/Assets | 0.1 | Lt Debt/Equity | 0.11 | Lt Debt/Cap. | 0.07 |
| Intrst Cov. | 109.54 | Inventory Turnover | 0.62 | Asset Turnover | 0.38 | Receivables Turnover | 6.56 |
| Enterprise Value | $46.10B | P/E Ratio | 44.38 |
| Forward P/E | 30.94 | PEG Ratio | — |
| P/S Ratio | 28.71 | P/B Ratio | 16.49 |
| P/CF Ratio | 56.02 | P/FCF Ratio | 89.54 |
| EPS | $24.38 | EPS Growth 1Y | 54.4% |
| EPS Growth 3Y | 140.44% | EPS Growth 5Y | 457.12% |
| Revenue Growth 1Y | -9.64% | Gross Margin | 0.4% |
| Operating Margin | 0.44% | Profit Margin | 0.44% |
| ROE | 0.2% | ROA | 0.17% |
| ROCE | 0.21% | Current Ratio | 1.7 |
| Quick Ratio | 0.86 | Cash Ratio | 0.19 |
| Debt/Equity | 0.15 | Interest Coverage | 109.54 |
| Altman Z Score | 12.46 | Piotroski Score | 5 |
Samsung Biologics (207940.KS) valuation & financials
Samsung Biologics (207940.KS) has a market capitalization of 50.08B KRW and trades at a price-to-earnings ratio of 44.4. It operates in the Healthcare sector (Biotechnology).
Samsung Biologics's revenue grew -9.6% over the last year.
Samsung Biologics's next earnings report is scheduled for October 27, 2026; analysts estimate EPS of 7.05 KRW. Check the earnings calendar to see all companies reporting this week.
Samsung Biologics (207940.KS) — frequently asked questions
When does Samsung Biologics (207940.KS) report earnings next?
Samsung Biologics is expected to report earnings on October 27, 2026. Analysts estimate EPS of 7.05 KRW.
What is Samsung Biologics's market cap?
Samsung Biologics (207940.KS) has a market capitalization of 50.08B KRW.
What is 207940.KS's P/E ratio?
Samsung Biologics trades at a price-to-earnings ratio of 44.4, with trailing twelve-month EPS of 24.38 KRW.
How fast is Samsung Biologics growing?
Samsung Biologics's revenue grew -9.6% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)